Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cutaneous side effects induced by indinavir.

D Calista1, A Boschini

  • 1Dermatology Unit "M. Bufalini" Hospital, 47023 Cesena, Italy.

European Journal of Dermatology : EJD
|June 10, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High- and intermediate-risk susceptibility variants in melanoma families from the Mediterranean area: A multicentre cohort from the MelaNostrum Consortium.

Journal of the European Academy of Dermatology and Venereology : JEADV·2023
Same author

Germline ATM variants predispose to melanoma: a joint analysis across the GenoMEL and MelaNostrum consortia.

Genetics in medicine : official journal of the American College of Medical Genetics·2021
Same author

Long-term remission of primary cutaneous neutrophil-rich CD30+ anaplastic large cell lymphoma treated with topical imiquimod. A case report.

Journal of the European Academy of Dermatology and Venereology : JEADV·2015
Same author

Polymorphous-like eruption of the heels.

Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia·2014
Same author

Development of squamous cell carcinoma after photodynamic therapy with methyl aminoleuvulinate.

The British journal of dermatology·2014
Same author

Sentinel lymph node biopsy or nodal observation in melanoma: study of an Italian series.

Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia·2013
Same journal

Erratum.

European journal of dermatology : EJD·2026
Same journal

sQUIZ your knowledge! A hidden flexural pattern revealed.

European journal of dermatology : EJD·2026
Same journal

sQuiz your knowledge! A new pigmented lesion on the back of a young woman.

European journal of dermatology : EJD·2026
Same journal

sQuiz your knowledge! Multiple yellowish papules in an adult.

European journal of dermatology : EJD·2026
Same journal

sQuiz your knowledge! When plaques turn into tumours.

European journal of dermatology : EJD·2026
Same journal

sQuiz your knowledge! A gradually progressive pigmented dermatosis.

European journal of dermatology : EJD·2026
See all related articles

HIV protease inhibitor indinavir causes significant skin side effects, including dryness, hair loss, and lipodystrophy, impacting patient quality of life and treatment adherence.

Area of Science:

  • Dermatology
  • Infectious Diseases
  • Pharmacology

Background:

  • HIV protease inhibitors are effective treatments for HIV/AIDS.
  • FDA approval was granted despite limited investigation into potential toxicities.
  • Indinavir is an HIV protease inhibitor used in combination therapy.

Purpose of the Study:

  • To investigate the cutaneous side effects of indinavir in HIV-positive patients.
  • To assess the impact of these side effects on patient quality of life and treatment compliance.

Main Methods:

  • A cohort of 101 HIV-positive patients received indinavir plus two nucleoside reverse transcriptase inhibitors (NRTIs).
  • Patient data was collected between January 1997 and August 1998.
  • Adverse events were recorded, and symptom regression was observed upon discontinuation of indinavir.

Related Experiment Videos

Main Results:

  • High incidence of cutaneous side effects: cheilitis (57.1%), diffuse dryness and pruritus (40.5%), asteatotic dermatitis (11.9%), scalp defluvium (11.9%), and peripheral lipodystrophy (14.3%).
  • A temporal relationship was observed between indinavir use and the onset of skin conditions.
  • Symptoms improved after discontinuing indinavir, confirming its role.

Conclusions:

  • Indinavir is associated with a high rate of significant cutaneous toxicities.
  • These side effects can negatively impact patient quality of life and treatment adherence.
  • Multidisciplinary management is essential for addressing these emerging toxicities.